A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients
Combination vaccine has been used since 1948 when diphtheria, tetanus, and pertussis antigens were grouped into a single product to vaccinate infants. Four hexavalent vaccines containing acellular pertussis are currently licensed in Europe out of which three are available in the European market. These hexavalent vaccines provide protection against six of the nine recommended diseases in children less than 12 months of age. A systematic literature review was done to evaluate the immunogenicity, long-term immunity, and safety data on Hexaxim (DT2aP-IPV-Hib-HBV) vaccination in infants.
Read more to know about the immune response and level of protection of the Hexaxim vaccination and its comparison to the other alternative vaccines in the market.
Introduction
Hexaxim is a hexavalent vaccine approved as primary and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b.
Areas Covered
To evaluate the immunogenicity and reactogenicity (safety) of Hexaxim (Hexyon,Hexacima) in primary and booster vaccine schedules; long-term antibody persistence; concomitant use with other childhood vaccines and use in immunocompromised infants. Hexaxim was found to be noninferior to other licensed hexavalent vaccines, being highly immunogenic for all toxoids/antigens and with an acceptable safety profile. It can be administered concomitantly with other childhood vaccines. Hexaxim can be given as a booster for infants primed with Infanrix Hexa and given in a pentavalent-hexavalent-pentavalent series. Hexaxim elicits a similar immune response and safety profile in human immunodeficiency virus (HIV) positive infants. It has the benefit of being a ready-to-use liquid formulation, minimizing dosage errors and preparation time.
Expert Opinion
Hexaxim has an acceptable safety profile and provides immunity against all six targeted diseases. It is an acceptable alternative to other hexavalent vaccines on the market. Further studies are required on the use of immunocompromised patients as well as the antibody persistence of each of the vaccine components.
For more details on the article
Dakin A, Borrow R, Arkwright PD. A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients. Expert Rev Vaccines. 2023 Jan-Dec;22(1):104-117. doi: 10.1080/14760584.2023.2161519. Epub 2022 Dec 26. PMID: 36545777.
MAT-IN-2301199-1.0-05/23